申请人:U C B S.A.
公开号:US05658938A1
公开(公告)日:1997-08-19
Substituted 4-(1,2,3,4-tetrahydro-1-naphthalenyl)-1H-imidazoles and 4-(2,3-dihydro-1H-inden-1-yl)-1H-imidazoles, their optical isomers and their racemic mixtures, their salts, methods for preparing them and therapeutic compositions containing them. These compounds have the general formula ##STR1## wherein n=1 or 2, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 =hydrogen, halogen, hydroxyl C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy, R.sub.5 = hydrogen of C.sub.1 -C.sub.4 alkyl with the proviso that R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5, cannot simultaneously be hydrogen when n is equal to 2. These new compounds exhibit anti-ischemic and anti-hypertensive activities.
替代了4-(1,2,3,4-四氢萘基)-1H-咪唑和4-(2,3-二氢茚基)-1H-咪唑,它们的光学异构体和它们的混合物,它们的盐,制备它们的方法以及含有它们的治疗组合物。这些化合物的一般式为:##STR1## 其中n=1或2,R.sub.1,R.sub.2,R.sub.3和R.sub.4=氢、卤素、羟基C.sub.1-C.sub.4烷基或C.sub.1-C.sub.4烷氧基,R.sub.5=氢或C.sub.1-C.sub.4烷基,但当n等于2时,R.sub.1,R.sub.2,R.sub.3,R.sub.4和R.sub.5不能同时为氢。这些新化合物具有抗缺血和抗高血压活性。